MPR Weekly Dose Podcast #268 — Childhood Immunization Schedule Changes Blocked; High Dose Wegovy Gets Green Light; Hidradenitis Suppurativa Tx Indication Expanded; Triple Therapy Show Significant Weight Loss
A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include ...
20 Mars 11min
MPR Weekly Dose Podcast #267 — Sotyktu, Leucovorin Gain Approval; Follicular Lymphoma Treatment Withdrawn; FDA to Review Potential Hypertension Drug
Sotyktu's approval expanded to encompass active psoriatic arthritis; the FDA approves leucovorin for rare disorder, not autism; safety concerns prompt Tazverik withdrawal; FDA to review potential new ...
12 Mars 12min
MPR Weekly Dose Podcast #266 — Generic Flovent HFA; Achondroplasia Tx Gains Approval; Dupixent Approved for Allergic Fungal Rhinosinusitis; Swallowable Gastric Balloon
Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; a...
6 Mars 11min
MPR Weekly Dose Podcast #265 — Wakix Approval Expanded; Psoriasis, Weight-Loss Combo Tx; Psilocybin Shows Promise in TRD; Remibrutinib for Chronic Inducible Urticaria; Injectable Regimen Benefits HIV Treatment Adherence
We explore the FDA's expansion of Wakix as the first non-scheduled treatment for pediatric cataplexy; a Taltz and Zepbound combo shows promise in skin clearance for patients with psoriasis and obesity...
20 Feb 12min
MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment
Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembro...
13 Feb 13min
MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review
Combo treatment aims to be latest to enter the weight loss space; Amgen refuses to remove drug from market despite FDA request; Novo Nordisk threatens legal action against Hims & Hers; an oral film fo...
6 Feb 15min
MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold
AAP maintains routine vaccine recs despite CDC changes; FDA warns of serious injury with wound and burn products; subcutaneous Alzheimer disease treatment under review; Cardamyst nasal spray available...
30 Jan 14min
MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression
New research on acetaminophen use during pregnancy; the chikungunya vaccine Ixchiq is withdrawn; FDA approves Nexplanon for up to 5 years of use; suicidal ideation warning removed from GLP-1s; at-home...
23 Jan 13min
